Skip to main content
https://pbs.twimg.com/media/EmOvg0HW4AIH1x7.jpg
CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC
Dr. Rachel Tate
07-11-2020
×